Zhe Huang

Zhe Huang

Auto-generated profile, based on publicly available information

Zhe Huang

Affiliation Department of Anorectal Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
JWJiayuan Wu
Jiayuan Wu
LCLin Chen
Lin Chen
YWYufeng Wang
Yufeng Wang
WTWenkai Tan
Wenkai Tan
ZHZhe Huang
Zhe Huang
Background: Numerous studies have reported the association between pretreatment serum aspartate transaminase to alanine transaminase (AST/ALT) ratio and prognosis in multiple cancers. However, the results remain controversial and no consensus has been reached. Thus, we conducted this meta-analysis to quantitatively assess the prognostic value of pretreatment AST/ALT ratio in solid tumors. Methods: A systematic literature search was conducted by using PubMed, EMBASE, Web of Science, Cochrane Library, and Wanfang databases, as well as several trial registry platforms, including ClinicalTrials.gov, WHO International Clinical Trials Registry Platform, and Chinese Clinical Trial Registry, up to April 5, 2019. HR and 95% CI for overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS) were calculated to estimate the effect size. Results: A total of 18 studies with 9,400 patients were included. Overall, a high level of pretreatment AST/ALT ratio was significantly associated with worse OS (pooled HR=1.70, 95% CI=1.38–2.09). The statistical significance was observed in all cancer types, including renal cell carcinoma (pooled HR=1.64, 95% CI=1.30–2.05), liver cancer (pooled HR=1.16, 95% CI=1.04–1.29), urinary tract urothelial carcinoma (pooled HR=1.96, 95% CI=1.53–2.51), bladder cancer (pooled HR =2.66, 95% CI=1.69–4.20), and other cancers (pooled HR=1.44, 95% CI=1.18–1.76). Moreover, an increased level of serum AST/ALT ratio predicted unfavorable CSS (pooled HR=2.07, 95% CI=1.74–2.46) and RFS (pooled HR=1.51, 95% CI=1.15–1.99). Conclusion: Elevated level of serum AST/ALT ratio before treatment is significantly associated with poor clinical outcomes of OS, CSS, and RFS in patients with solid tumors. Pretreatment AST/ALT ratio can serve as a useful prognostic predictor for malignant patients.

1 March 2020 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
ZHZhe Huang
Zhe Huang
CLChun-An Liu
Chun-An Liu
PCPeng-Zhu Cai
Peng-Zhu Cai
FXFei-Peng Xu
Fei-Peng Xu
WZWen-Jing Zhu
Wen-Jing Zhu
HJHai-Ping Jiang
Hai-Ping Jiang
Background: Omega 3 polyunsaturated fatty acid (Omega-3PUFA) is one of the essential nutrients for human body involved in intracellular metabolic regulation and cell signaling. Previous studies have shown that Omega-3PUFA is involved in the pathogenesis of digestive system tumors, including colorectal cancer (CRC), however, the effects of Omega-3PUFA on CRC has not been fully elucidated. In the current study, we evaluated whether Omega-3PUFA can alleviate N-methyl-N-nitrosourea(MNU) induced CRC in a rat model and illustrated the potential mechanism. Methods: The effects of Omga-3PUFA on MNU-induced colorectal cancer in rats were analyzed by in vivo experiments. The viability, apoptosis, colony formation and invasion of CRC cells treated with Omga-3PUFA were detected by CCK8, flow cytometry, clone formation assay and transwell invasion assay. The expression of apoptosis-related proteins in CRC cells treated with Omga-3PUFA was detected by Western blotting. Finally, after adding PI3K activator, the viability, apoptosis and protein expression of CRC cells treated with Omga-3PUFA were detected by CCK8, flow cytometry and Western blotting. Results: Our results showed that Omega-3PUFA attenuated MNU-induced CRC in rats and inhibited AKT/Bcl-2 signaling in rats. In addition, Omega-3PUFA inhibited CRC cell proliferation and induces CRC cell apoptosis. Moreover, Omega-3PUFA inhibited CRC cell colony formation and invasion, and inhibited PI3K/AKT/Bcl-2 signaling in CRC cells. Furthermore, The effects of Omega-3PUFA on cell proliferation and apoptosis were inhibited by blocking PI3K/AKT signaling. Conclusion: Omega-3PUFA can attenuate MNU-induced colorectal cancer in rats by blocking PI3K/AKT/Bcl-2 signaling, which suggests that Omega-3PUFA may be a potent agent for CRC treatment.

30 May 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ZHZhe Huang
Zhe Huang
XHXu Hu
Xu Hu
YWYiqiu Wei
Yiqiu Wei
YLYousheng Lai
Yousheng Lai
JQJiaming Qi
Jiaming Qi
PCPengzhu Cai
Pengzhu Cai
The ADAMTS Like 2 (ADAMTSL2) mutation has been identified to be associated with different human genetic diseases. The role of ADAMTSL2 is unclear in colorectal cancer (CRC). The study investigated the expression of ADAMTSL2 in both pan cancer and CRC, using data from The Cancer Genome Atlas (TCGA) database to assess its diagnostic value. The study examined the correlation between ADAMTSL2 expression levels and clinical characteristics, as well as prognosis in CRC. The study explored potential regulatory networks involving ADAMTSL2, including its association with immune infiltration, immune checkpoint genes, tumor mutational burden (TMB) / microsatellite instability (MSI), tumor stemness index (mRNAsi), and drug sensitivity in CRC. ADAMTSL2 expression was validated using GSE71187 and quantitative real-time PCR (qRT-PCR). ADAMTSL2 was aberrantly expressed in pan cancer and CRC. An increased level of ADAMTSL2 expression in patients with CRC was significantly associated with the pathologic N stage (p< 0.001), pathologic stage (p< 0.001), age (p< 0.001), histological type (p< 0.001), and neoplasm type (p= 0.001). The high expression of ADAMTSL2 in patients with CRC was found to be significantly associated with a poorer overall survival (OS) (HR: 1.67; 95% CI: 1.18–2.38;p= 0.004), progression-free survival (PFS) (HR: 1.55; 95% CI: 1.14–2.11;p= 0.005) and disease-specific survival (DSS) (HR: 1.83; 95% CI: 1.16–2.89;p= 0.010). The expression of ADAMTSL2 in patients with CRC (p= 0.009) was identified as an independent prognostic determinant. ADAMTSL2 was associated with extracellular matrix receptor (ECM-receptor) interaction, transforming growth factor β (TGF-β) signaling pathway, and more. ADAMTSL2 expression was correlated with immune infiltration, immune checkpoint genes, TMB / MSI and mRNAsi in CRC. ADAMTSL2 expression was significantly and negatively correlated with 1-BET-762, Trametinib, and WZ3105 in CRC. ADAMTSL2 was significantly upregulated in CRC cell lines. The high expression of ADAMTSL2 is significantly correlated with lower OS and immune infiltration of CRC. ADAMTSL2 may be a potential prognostic biomarker and immunotherapeutic target for CRC patients.

1 April 2021 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
NZNa Zhang
Na Zhang
BZBowen Zheng
Bowen Zheng
XYXiaojun Yao
Xiaojun Yao
Huang XiaomingHuang Xiaoming
Huang Xiaoming
JDJingjing Du
Jingjing Du
WMWenzhe Ma
Wenzhe Ma

18 November 2023 in Current Medical Science
Verified
Journal Article
Closed access
PDF file
ZMZhi-Gang Ma
Zhi-Gang Ma
YLYing-Xue Liu
Ying-Xue Liu
NZNing Zou
Ning Zou
ZHZhe Huang
Zhe Huang
MWMing Wang
Ming Wang
LCLigang Chen
Ligang Chen